FDA Commissioner Resignation and Its Impact on Drug Approvals
Decision brief
Answer first · skim in under a minute
This week, the FDA Commissioner announced their resignation, raising questions about the future of drug approvals. Here's what it means for the biopharma industry.
FDA Commissioner Resignation and Its Impact on Drug Approvals is a May 2026 story, not an October 2024 Califf rumor. FDA records show Marty Makary's commissioner term ran March 25, 2025 to May 13, 2026, with Kyle Diamantas now listed as commissioner while novel approvals kept posting.
Contents9 sections
Key Takeaways
- FDA lists Martin A. Makary as commissioner from March 25, 2025 through May 13, 2026.
- FDA leadership profiles now name Kyle Diamantas, J.D., as Commissioner of Food and Drugs.
- Robert Califf's second commissioner term ended January 20, 2025 with the administration change, not via an October 26, 2024 resignation.
- FDA's 2026 novel-drug table continued to post May approvals on and after May 13, including Beqalzi and later May 22–29 entries.
What do FDA records say about the commissioner change?
FDA's official commissioners chronology lists Martin A. Makary, M.D., M.P.H., from March 25, 2025 to May 13, 2026. The same roster shows Robert M. Califf's most recent term ending January 20, 2025.
Makary's FDA biography page repeats the March 25, 2025 to May 13, 2026 window and notes his Senate confirmation as the 27th Commissioner of Food and Drugs. Treat those FDA pages as the dated leadership record for diligence memos.
Secondary pieces that invent an October 26, 2024 Califf resignation conflict with FDA's published timeline and should be discarded.
Who is running FDA now?
FDA's leadership profiles currently list Kyle Diamantas, J.D., as Commissioner of Food and Drugs.
A permanent Senate-confirmed successor may still follow, but sponsor teams should address correspondence and meeting requests to the leadership names FDA publishes now, not to a departed commissioner.
For historical context on Makary's arrival, FDA's March 2025 swearing-in announcement remains the primary source for his confirmation and opening statement.
Did drug approvals freeze after the May 2026 exit?
No public freeze appears on FDA's novel-drug chronology. The Novel Drug Approvals for 2026 table lists Beqalzi (sonrotoclax) on May 13, 2026, the same calendar end-date FDA shows for Makary's tenure.
Later May novel entries on that table include Hepcludex on May 22, Decnupaz on May 27, and Zaynich, Xocova, and Cypsedo on May 29. Those dated clearances are hard evidence that CDER kept posting novel decisions after the leadership turnover.
For product-level detail on one May oncology action, see FDA's Beqalzi accelerated approval notice.
How should sponsor teams manage PDUFA and meeting risk?
Leadership change can reshape rhetoric and enforcement emphasis without automatically rewriting user-fee clocks. Sponsors should verify goal dates in their own correspondence and on Drugs@FDA rather than assume a blanket pause.
Practical steps: confirm the review division contact, ask whether any information request is tied to a new policy memo, and document whether a Type A/B/C meeting date still holds. Do not treat social media claims as substitutes for FDA written notice.
Pipeline teams can cross-check recent clearance patterns against NovaPharma's May 2026 drug approvals roundup and the Bizengri priority-review case.
What should investors watch in the next 90 days?
Watch three observables that do not require insider gossip. First, whether FDA posts a permanent commissioner nomination and confirmation. Second, whether novel-drug and efficacy-supplement cadence on FDA tables slows versus the May 2026 pace. Third, whether major review-office vacancies appear on the leadership profiles page.
Also watch tobacco, food, and vaccine policy headlines separately from human drug review metrics. Mixing those portfolios into one "approvals are frozen" thesis overstates what the novel-drug table currently shows.
For manufacturing and evidence readiness around new clearances, see NovaPharma's manufacturing pipeline approvals evidence brief.
Related NovaPharma coverage
- May 2026 FDA drug approvals regulatory roundup
- Bizengri FDA national priority for rare bile duct cancer
- Manufacturing pipeline approvals: what the evidence confirms
Frequently Asked Questions
When did Marty Makary's FDA commissioner tenure end?
FDA's commissioners roster lists Martin A. Makary, M.D., M.P.H., as commissioner from March 25, 2025 to May 13, 2026.
Who leads FDA after Makary's departure?
FDA's leadership profiles list Kyle Diamantas, J.D., as Commissioner of Food and Drugs following Makary's May 2026 exit.
Did May 2026 novel drug approvals stop after the leadership change?
No. FDA's Novel Drug Approvals for 2026 table still lists May clearances such as Beqalzi on May 13 and later May entries including Hepcludex on May 22 and three May 29 approvals.
Primary Sources
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
